Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK ...

Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA)?in collaboration with the Triple Negative Breast Cancer Foundation, the American Association for Cancer Research (AACR), and Nueva Vida?has launched ...

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...

November 19, 2024--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm ... Smither served as the ...

With FDA approval in the bag for its AI-based aortic stenosis diagnostic tool, Echo IQ is focused on commercialisation over the coming years.

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

Remdesivir plus dexamethasone vs dexamethasone alone reduces the risk of mortality among patients hospitalized with COVID-19.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.

Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...